Cowen And Company, LLC Aurinia Pharmaceuticals Inc. Call Options Transaction History

Cowen And Company, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $958,342 - $1.78 Million	-53,900 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$10.93 - $23.55 $447,037 - $963,195	40,900 Added 314.62%	53,900 $330,000
Q2 2021 Aug 13, 2021	SELL	$10.0 - $14.52 $120,000 - $174,240	-12,000 Reduced 48.0%	13,000 $37,000
Q1 2021 May 04, 2021	SELL	$12.3 - $18.73 $120,540 - $183,554	-9,800 Reduced 28.16%	25,000 $3,000
Q4 2020 Feb 08, 2021	BUY	$12.94 - $16.05 $450,312 - $558,540	34,800 New	34,800 $90,000
Q1 2020 May 11, 2020	SELL	$11.34 - $21.46 $283,500 - $536,500	-25,000 Closed	0 $0
Q4 2019 Feb 11, 2020	BUY	$3.88 - $21.42 $97,000 - $535,500	25,000 New	25,000 $254,000

209

58.7M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.15B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Cowen And Company, LLC, based on Form 13F filings with the SEC.

Stay updated on Cowen And Company, LLC with notifications on news.